A genome-wide association study involving 27,885 participants has identified genetic variations that affect the efficacy and side effects of GLP-1 receptor agonists, a class of drugs used for weight loss and diabetes management. The study, published in Nature on April 8, 2026, found a missense variant in the GLP1R gene associated with increased weight-loss efficacy, with approximately 0.76 kg additional weight loss per copy of the effect allele [1][2].
Variants in both the GLP1R and GIPR genes were linked to nausea or vomiting side effects, with the GIPR association being specific to users of tirzepatide, a GLP-1 receptor agonist [1][2]. Ruth Loos, a genetic epidemiologist at the University of Copenhagen, noted that individuals with two copies of the GLP1R variant experienced more than 10 percent greater weight loss compared to the study population average [2][3].
The findings were replicated in the NIH’s All of Us database, although some other studies did not observe a similar effect, according to Loos [3]. Andres Acosta of the Mayo Clinic stated that the study supports precision obesity approaches, emphasizing that many genetic variants contribute to differences in GLP-1 drug response [3].
The Washington Post reported that the 23andMe Research Institute is integrating a genetic report based on these findings into their “Total Health” product [4]. Adam Auton, Vice President of Human Genetics at 23andMe, highlighted the role of genetics in personalizing treatment plans [4].
Reuters noted that individuals predicted to have a greater weight-loss effect indeed lost more weight, reinforcing the potential for genetic testing to guide treatment [2].
What Is Known
The study provides evidence that genetic variations in the GLP1R and GIPR genes can influence both the efficacy and side effects of GLP-1 receptor agonists. These findings have been corroborated by multiple sources and replicated in a major database, supporting the potential for personalized medicine in treating obesity and diabetes [1][2][3].
What Remains Unclear
While the study’s findings are significant, some other studies have not found similar effects, indicating that further research is needed to fully understand the genetic factors influencing GLP-1 drug response. Additionally, the impact of other genetic variants, such as those identified in unconfirmed studies, remains to be clarified [3][5].
This article was generated by Bluxle's AI system based on research from multiple news sources. All facts are sourced and cited below. The AI is designed to be neutral and fact-based with no editorial opinion.
Sources & Citations
Weighted by citation frequency — sources cited more often carry greater influence.
Research Basis
This article was researched across outlets representing a range of political perspectives. Only sources whose facts are directly used appear in Sources & Citations above.
Report an Issue
Tell us what you noticed. Our editors will review it.
✓ Report received. Thank you!